Current Products

Summary of Product Characteristics (SPC)


Patient Information Leaflet (PIL)

Risk Minimisation

Risk Minimisation materials (e.g. educational brochures, patient alert cards, posters etc) are intended to improve the use of a medicine by positively influencing health professionals and patients to reduce the risk and/or the severity of adverse reactions associated with a particular medicine.

These materials are additional to the medicine’s Summary of Product Characteristics (SmPC) and Patient Information Leaflet and their requirements are part of the product EU Risk Management Plan.

Only some medicines have a set of tailored risk minimisation materials developed for this purpose.
If required, these materials are reviewed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

To access risk minimisation materials (where available electronically) for our medicines, please click on the link below to the electronic Medicines Compendium (eMC) website. Please note: after clicking link below you will then need to use the search function to access a medicine's risk minimisation materials, click on either the SmPC or Patient Information Leaflet and then click on the "Risk Materials" banner at the top.

When you click on the hyperlink below you will be moving away from a BMS website to a website for which BMS has no responsibility.


https://www.medicines.org.uk/emc/

If you would like a hard copy of a BMS medicine's risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 7311736, email: medical.information@bms.com)with your specific request.

Date of preparation: May 2017 466UK1700521-01